ACCELERON PHARMA INC. Patent applications |
Patent application number | Title | Published |
20150299677 | USE OF ACTIVIN RECEPTOR-LIKE KINASE 1 (ALK-1) ANTAGONISTS IN THE TREATMENT OF CANCER - Some aspects of this disclosure provide methods and compositions for the treatment of cancer, for example, head and neck cancer, in a subject using ALK1 inhibitors, e.g., ALK1-ECD polypeptides, ALK1-Fc fusion proteins, or ALK1-inhibitory antibodies. In some embodiments, methods and compositions are provided for treating certain cancers with ALK1 inhibitors in combination with a chemotherapeutic platinum agent. In some embodiments, methods are provided for identifying whether a cancer in a subject will react to treatment with an ALK1 antagonist, either alone or in combination with a chemotherapeutic platinum agent, for example, based on a determination that the cancer or the subject is positive for human papilloma virus. | 10-22-2015 |
20150023970 | ACTRIIB PROTEINS AND VARIANTS AND USES THEREFORE RELATING TO UTROPHIN INDUCTION FOR MUSCULAR DYSTROPHY THERAPY - In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. | 01-22-2015 |
20150010555 | COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE - Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites. | 01-08-2015 |
20140328845 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 11-06-2014 |
20140314759 | ISOLATED NUCLEOTIDE SEQUENCES ENCODING GDF TRAPS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 10-23-2014 |
20140205600 | METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 07-24-2014 |
20140199317 | ACTRIIA BINDING AGENTS AND USES THEREOF - The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same. | 07-17-2014 |
20140193425 | TREATMENT OF CANCER WITH ALK1 ANTAGONISTS - Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided. | 07-10-2014 |
20140079700 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 03-20-2014 |
20130344067 | ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction. | 12-26-2013 |
20130244324 | ISOLATED GDF TRAP POLYPEPTIDE - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 09-19-2013 |
20130243743 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 09-19-2013 |
20130209462 | CERBERUS/COCO DERIVATIVES AND USES THEREOF - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives. | 08-15-2013 |
20130195862 | ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION - In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation. | 08-01-2013 |
20130189269 | ACTRIIB BINDING AGENTS AND USES THEREOF - The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same. | 07-25-2013 |
20130184210 | VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand. | 07-18-2013 |
20130177559 | Truncated ActRIIb-Fc Fusion Protein - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue. | 07-11-2013 |
20130108650 | ACTRIIB BINDING AGENTS AND USES THEREOF | 05-02-2013 |
20130101603 | BMP-ALK3 ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins. | 04-25-2013 |
20130084291 | COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE - Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites. | 04-04-2013 |
20130071393 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING ANEMIA USING A COMBINATION OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 03-21-2013 |
20130065299 | ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand. | 03-14-2013 |
20130040896 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 02-14-2013 |
20130039910 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 02-14-2013 |
20130029908 | CERBERUS/COCO DERIVATIVES AND USES THEREOF - The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives. | 01-31-2013 |
20130004489 | ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. | 01-03-2013 |
20120213782 | BMP10 ANTIBODIES AND RELATED METHODS - In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10. | 08-23-2012 |
20120202739 | GDF3 ANTIBODIES AND RELATED METHODS - In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3. | 08-09-2012 |
20120183540 | METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 07-19-2012 |
20120156204 | METHODS FOR INCREASING ADIPONECTIN - In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations. | 06-21-2012 |
20120148588 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 06-14-2012 |
20120128668 | METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTIVIN ANTIBODY - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 05-24-2012 |
20120058115 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 03-08-2012 |
20120015877 | USE OF GDF TRAPS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 01-19-2012 |
20120003218 | ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 01-05-2012 |
20110218147 | ACTIVIN-ACTRIIA ANTAGONISTS FOR INHIBITING GERM CELL MATURATION - In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation. | 09-08-2011 |
20110171218 | COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE - Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites. | 07-14-2011 |
20110135638 | ACTRIIB PROTEINS AND VARIANTS AND USES THEREFORE RELATING TO UTROPHIN INDUCTION FOR MUSCULAR DYSTROPHY THERAPY - In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. | 06-09-2011 |
20110129469 | METHODS FOR TREATING FATTY LIVER DISEASE - In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease. | 06-02-2011 |
20110092670 | VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand. | 04-21-2011 |
20110070233 | ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided. | 03-24-2011 |
20110046057 | USES OF CERBERUS AND DERIVATIVES THEREOF - The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. | 02-24-2011 |
20110038831 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 02-17-2011 |
20100322925 | ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 12-23-2010 |
20100316644 | TRUNCATED ACTRIIB-FC FUSION PROTEINS - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue. | 12-16-2010 |
20100310577 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 12-09-2010 |
20100267133 | ACRTIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand. | 10-21-2010 |
20100266612 | BMP-ALK3 ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins. | 10-21-2010 |
20100204092 | Activin-actrii antagonists and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 08-12-2010 |
20100160225 | Lefty, lefty derivatives and uses thereof - The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders. | 06-24-2010 |
20100068215 | Use of GDF traps to increase red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 03-18-2010 |
20100028332 | Antagonists of actriib and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 02-04-2010 |
20100028331 | Antagonists of activin-actriia and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 02-04-2010 |
20100015144 | Methods for dosing an activin-actriia antagonist and monitoring of treated patients - In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient. | 01-21-2010 |
20100008918 | Methods for dosing an actriib antagonist and monitoring of treated patients - In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient. | 01-14-2010 |
20090311748 | HEART20049410 POLYPEPTIDES AND METHODS OF MAKING THE SAME - Novel full-length cDNAs are provided. | 12-17-2009 |
20090311252 | Anti-activin antibodies and uses for promoting bone growth - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 12-17-2009 |
20090304691 | ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo. | 12-10-2009 |
20090163417 | Activin-actrii antagonists and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 06-25-2009 |
20090149372 | BMP10 propeptides and related methods - In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10. | 06-11-2009 |
20090142333 | Activin-actriia antagonists and uses for promoting bone growth in cancer patients - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. | 06-04-2009 |
20090118188 | Activin-actriia antagonists and uses for decreasing or inhibiting FSH secretion - In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation. | 05-07-2009 |
20090099086 | Activin-ActRIIa antagonists and uses for promoting bone growth - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 04-16-2009 |
20090098114 | ALK7 and myostatin inhibitors and uses thereof - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 04-16-2009 |
20090098113 | Activin-ActRIIa antagonists and uses for promoting bone growth - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 04-16-2009 |
20090082270 | Uses of cerberus, Coco and derivatives thereof - The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. | 03-26-2009 |
20090074768 | Activin-actriia antagonists and uses for treating or preventing breast cancer - In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans. | 03-19-2009 |
20090042780 | Modified TGF-Beta Superfamily Polypeptides and Related Methods - The disclosure relates to modified TGF-beta polypeptides. Certain modified polypeptides disclosed herein are chimeric, containing a conserved framework portion from one protein of this family (e.g., Nodal) and variable loops that mediate receptor interaction derived from a second protein of this family (e.g., BMP-2). The chimeras will generally be designed so as to mimic a biological effect of the family member from which the variable loops are derived. Other modified TGF-polypeptides disclosed herein have one or more post-translational modifications that may be situated in one or more core domains. | 02-12-2009 |
20090005308 | Variants derived from ACTRIIB and uses therefor - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand. | 01-01-2009 |
20080241164 | BMP-3 antibodies and related methods - The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth. | 10-02-2008 |